Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jilin Jian Yisheng Pharmaceutical Co., Ltd. (002566.SZ)
Ji'an, CN
Jilin Jian Yisheng Pharmaceutical Co., Ltd. is an enterprise based in Ji'an, China, established in 1997. The company specializes in the production and distribution of a diverse array of goods across the Chinese market. Its offerings include various pharmaceutical products, traditional Chinese herbal medicines, cosmetic items, and food products. Within its medical and health divisions, the firm provides goods in formats such as capsules, injections, tablets, and granules, with a particular emphasis on specialized medicinal products derived from Ginseng, as well as a selection of bee-related products.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.70% | -7.96% | -14.96% | -16.86% | -14.23% | -7.60% | -11.76% | -18.12% | -18.40% | -37.78% | -47.19% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-4.2% Q1'26: +9.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-45.3% Q1'26: +36.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+11.9% ★ Q1'26: +19.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+6.7% ★ Q1'26: +4.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+1.9% ★ Q1'26: +1.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×4.96× ★ Q1'26: 14.90× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
|---|---|
| Revenue |
975.09M
est: 1.50B (-34.9%)
|
| EBITDA |
162.98M
est: 292.00M (-44.2%)
|
| EBIT |
122.76M
est: 207.22M (-40.8%)
|
| Net Income |
69.08M
|
| SGA |
598.92M
est: 777.52M (-23.0%)
|
| EPS |
0.21
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jian Tao Bi | Deputy GM, Chief Financial Officer & Non-Independent Director | — | male |
| Tiejun Li | Deputy GM & Secretary of the Board | — | male |
| Wei Meng | Deputy General Manager | — | male |
| Xiaomin Xue | General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002566.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
